| Accession |
PRJCA013957 |
| Title |
CKJX839A1CN01-biomarker data |
| Relevance |
Medical |
| Data types |
clinical data and (LDL-C, HDL-C, TC, Lp (a), TG)
|
| Organisms |
Homo sapiens
|
| Description |
For drugs such as inclisiran that have been approved by major health authorities (HAs) worldwide but not in China, several special territories in China can provide drug early access to Chinese patients. A real-world evidence study in these territories can provide data of effectiveness and safety of inclisiran in Chinese population. This study will utilize real-world data from EMR database to serve as the "external control". The purpose of this study is to compare the effectiveness of inclisiran as an add-on therapy (or monotherapy in statin-intolerant cases) in real-world settings with current SoC in a matched historical cohort of patients who receive SoC in EMR database.ulation. |
| Sample scope |
Data collected only, no samples collected. |
| Release date |
2022-12-20 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Novarits
|
Clinical trail fee
|
NA
|
CKJX839A1CN01
|
|
|
| Submitter |
shijuan
lu (1157416676@qq.com)
|
| Organization |
Haikou people's Hospital |
| Submission date |
2022-12-19 |
